Estimating the Impact of Alternative Programmatic Cotrimoxazole

2 Strategies on Mortality Among Children Born to Mothers with HIV:

3 A Modelling Study

Abstract: 333

Article: 3935

Shrey Mathur¹, Melanie Smuk¹, Ceri Evans^{1,2}, Catherine J Wedderburn^{3,4}, Diana M Gibb³, Martina Penazzato⁵, Andrew J Prendergast^{1,2} ¹ Blizard Institute, Queen Mary University of London, London, United Kingdom ² Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe ³ Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom ⁴ Department of Paediatrics and Child Health and Neuroscience Institute, University of Cape Town, Cape Town, South Africa ⁵ Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland Corresponding author: Dr Shrey Mathur, Centre for Genomics and Child Health, Blizard Institute, 4 Newark Street, London E1 2AT, UK. s.mathur@gmul.ac.uk Word count

Abstract

BACKGROUND

World Health Organization guidelines recommend cotrimoxazole prophylaxis for children who are HIV-exposed until infection is excluded and vertical transmission risk has ended. While cotrimoxazole has benefits for children with HIV, there is no mortality benefit for children who are HIV-exposed but uninfected, prompting a review of global guidelines. Here, we model the potential impact of alternative cotrimoxazole strategies on mortality in children who are HIV-exposed.

METHODS AND FINDINGS

Using a deterministic compartmental model, we estimated mortality in children who are HIV-exposed from 6 weeks to 2 years of age in four high-burden countries: Côte d'Ivoire, Mozambique, Uganda, and Zimbabwe. Vertical transmission rates, testing rates, and antiretroviral therapy uptake were derived from UNAIDS data, trial evidence, and meta-analyses. We explored six programmatic strategies: maintaining current recommendations; shorter cotrimoxazole provision for three, six, nine or twelve months; and starting cotrimoxazole only for children diagnosed with HIV.

Modelled alternatives to the current strategy increased mortality to varying degrees; countries with high vertical transmission had the greatest mortality. Compared to current recommendations, starting cotrimoxazole only after a positive HIV test had the greatest predicted increase in mortality: Mozambique (961 excess annual deaths; excess mortality 339 per 100,000 HIV-exposed children; risk ratio (RR) 1.06), Uganda (491; 221; RR 1.04), Zimbabwe (352; 260; RR 1.05), Côte d'Ivoire (125; 322; RR 1.06). Similar effects were observed for three, six, nine, and twelve-month strategies. Increased mortality persisted but was attenuated when modelling lower cotrimoxazole uptake, smaller mortality benefits, higher testing coverage, and lower vertical transmission rates. The study is limited by uncertain estimates of cotrimoxazole coverage in programmatic settings; an inability to model increases in mortality arising from antimicrobial resistance due to limited surveillance data in sub-Saharan Africa; and lack of a formal health economic analysis.

CONCLUSIONS

- Changing current guidelines from universal cotrimoxazole provision for children who are HIVexposed increased predicted mortality across the four modelled high-burden countries, depending
 on test-to-treat cascade coverage and vertical transmission rates. These findings can help inform
 policymaker deliberations on cotrimoxazole strategies, recognising that the risks and benefits differ
- 78 across settings.

Author Summary

Why Was This Study Done?

- Cotrimoxazole prophylaxis is recommended in World Health Organization (WHO) guidelines
 for all children born to mothers with HIV until HIV infection has been excluded by an ageappropriate HIV test to establish the final diagnosis after complete cessation of
 breastfeeding.
- Though there is a proven mortality benefit for children who acquire HIV, recent trial evidence
 has shown that cotrimoxazole does not reduce mortality for majority of children who are
 HIV-exposed uninfected (HEU), which has led to countries considering changing their
 guidelines.
- In many resource-limited settings, however, it is difficult to reliably distinguish children with HIV from children who are HEU, due to incomplete coverage of early infant diagnosis (EID) of HIV.
- There is a need to model to what extent alternative cotrimoxazole strategies, which either do
 not provide universal cotrimoxazole for all infants who are HIV-exposed, or provide it for a
 shorter duration, would be predicted to increase mortality in different settings among
 infants who acquire HIV but are undiagnosed.

What Did the Researchers Do and Find?

- This study uses mathematical modelling based on epidemiological data from four highburden settings (Côte d'Ivoire, Mozambique, Uganda, and Zimbabwe) to estimate the effect on mortality of alternative programmatic cotrimoxazole strategies.
- The model incorporates the HIV status of the infant, perinatal and postnatal transmission
 rates, testing rates, and mortality benefits from trial evidence for cotrimoxazole and
 antiretroviral therapy (ART) across six different programmatic strategies: maintaining current
 recommendations; reducing the duration of cotrimoxazole provision to three, six, nine or
 twelve months; or starting cotrimoxazole only once a child tests positive for HIV.
- We demonstrate that changing the current strategy is predicted to increase mortality in all
 four settings, with the greatest increase in mortality in countries with the highest vertical
 transmission rates.
- Increased predicted mortality persisted in sensitivity analyses considering conservative model estimates, although cotrimoxazole had fewer predicted benefits when vertical

transmission rates were lowered, testing coverage improved or uptake of cotrimoxazole was reduced.

What Do These Findings Mean?

- Changing the current strategy of cotrimoxazole provision for all children born to mothers
 with HIV is estimated to increase mortality in these four high-burden settings to varying
 degrees as countries continue to scale up Prevention of Mother to Child Transmission of HIV
 (PMTCT) and EID coverage.
- Cotrimoxazole continues to provide important protection to children who acquire HIV and are missed by gaps in the test-to-treatment cascade, but does not replace the importance of timely testing and treatment.
- Our study is limited by lack of cost-effectiveness analysis, lack of data on cotrimoxazole uptake, and limited antimicrobial resistance surveillance data in sub-Saharan Africa.
- Policymakers need to weigh the risks and benefits of cotrimoxazole prophylaxis through any
 change to current recommendations, noting that these differ across settings: where lower
 vertical transmission rates and improved testing and treatment uptake occurs, the estimated
 mortality benefits of cotrimoxazole are attenuated.

Introduction

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

130

Vertical transmission of HIV occurs during pregnancy, labour, delivery, and breastfeeding. Despite substantial reductions in vertical transmission globally due to increased uptake of antiretroviral therapy (ART) among pregnant and breastfeeding women, transmission rates remain at 9% for Eastern and Southern Africa and 21% for Western and Central Africa [1]. Poor uptake of prevention of mother-to-child transmission (PMTCT) interventions arises due to late antenatal booking, low rates of HIV testing and ART initiation, and disengagement with services during pregnancy or breastfeeding [2]. Infants acquiring HIV have rapid disease progression, with over 50% mortality by two years of age without infant ART [3]. Given ongoing high transmission rates, limited PMTCT uptake, and rapid progression in undiagnosed children, programmatic strategies are needed to reduce morbidity and mortality among children born to mothers with HIV, until elimination of vertical transmission is achieved. Cotrimoxazole is an inexpensive, well-tolerated, broad-spectrum antibiotic, which is recommended in World Health Organization (WHO) guidelines for all infants born to mothers with HIV from age 4-6 weeks until the end of HIV-exposure – typically defined as the end of breastfeeding, 18 months of age, or conclusive determination of being HIV-free [4,5]. There is strong evidence of mortality benefit from receiving cotrimoxazole among children with HIV. The CHAP trial demostrated a 43% reduction in mortality in ART-naïve children, and the ARROW trial showed that benefits of cotrimoxazole persist despite immune reconstitution on long-term ART [6,7]. Conversely, there is no evidence of mortality benefit from cotrimoxazole among children who are HIV-exposed but uninfected (HEU) [8, 9]. Furthermore, there are concerns about antibiotic resistance and microbiome dysbiosis with cotrimoxazole use [10]. Given the distinct cotrimoxazole strategy required in each group, there is a critical need to identify and distinguish children with HIV from children who are HEU across different periods of transmission. HIV testing for children has improved substantially over the past two decades. However, only 62% of infants globally currently receive the recommended virological test within two months of birth [1]. Overall, 40% of children with HIV therefore remain undiagnosed [11]. Even where infants are tested, challenges remain across the testing-to-treatment cascade. These include lengthy turnaround times for results, lack of integration with child health services, loss to follow-up, and delayed ART initiation [12,13]. Vertical transmission through prolonged breastfeeding now accounts for over half of transmissions in some settings, and necessitates longitudinal testing [2]. WHO guidelines encourage testing of HIV-exposed children at nine months of age and after complete cessation of breastfeeding [4].

A recent systematic review highlighted the lack of mortality benefit from cotrimoxazole for children who are HEU [14]. However, in settings with insufficient PMTCT and inadequate early infant diagnosis (EID) programmes, there is a substantial population of undiagnosed infants with HIV, who may benefit from cotrimoxazole prophylaxis to reduce mortality. In other settings, where PMTCT uptake and EID coverage are high, and the majority of infants are HEU, the risk-benefit balance of cotrimoxazole may differ. Therefore, given these competing concerns, the optimal duration of cotrimoxazole prophylaxis needs to be determined. Here, we model the mortality impact of alternative cotrimoxazole strategies in four high-burden settings.

Methods

Model Structure

We constructed a deterministic compartmental model with a decision tree to compare alternative cotrimoxazole prophylaxis strategies for children who are HIV-exposed. The model aimed to mimic epidemics in four high-burden countries: Zimbabwe (ZWE), Côte d'Ivoire (CIV), Mozambique (MOZ) and Uganda (UGA). These countries represent differing sub-Saharan African contexts and have sufficient information to enable estimates for the model parameters. The model structure and all estimates or assumptions applied are shown in Fig 1 and Supplementary Table S1. The study did not have a prospective protocol. This study is reported as per the Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guideline (S1 Checklist).

The model estimates mortality from 6 weeks of age, when cotrimoxazole initiation is recommended, to 24 months of age. Testing timepoints were assigned at 6 weeks (defined as EID), at 9 months and at 18 months (defined as end of breastfeeding, EoB). At 6 weeks, infants are categorised according to whether they have acquired perinatal HIV and whether they undergo early infant diagnosis. Children who are HIV-free at 6 weeks may acquire HIV through breastfeeding and may or may not receive additional HIV testing at 9 months and end of breastfeeding. Cotrimoxazole was provided based on programmatic strategy (Fig 1B). If the child was diagnosed with HIV, cotrimoxazole was started in conjunction with ART. ART was initiated only after a positive HIV test and was not initiated after negative or missed tests (i.e., for undiagnosed cases). Disease progression was incorporated through survival probabilities for children with HIV and children who are HIV-exposed uninfected, extracted from trial data and natural history studies [3,15]. Mortality occurs at each stage of the model, and depends on current age, HIV status, ART use and cotrimoxazole use. We defined model parameters for HIV transmission, coverage of EID and ART uptake using epidemiological data, as outlined below,

while the effects of cotrimoxazole and ART on mortality were derived from trials and meta-analyses (Supplementary Table 1) [2,3,15-18].

Compartments were created to compare strategies of receiving cotrimoxazole: (1) from age 6 weeks to end of breastfeeding (current WHO strategy; base case), (2) from 6 weeks to 12 months, (3) from 6 weeks to 9 months, (4) from 6 weeks to 6 months, (5) from 6 weeks to 3 months, and (6) only once a positive HIV test result is confirmed. In all strategies, we assume that infants testing positive for HIV will start cotrimoxazole.

The primary outcome of deaths among children who are HIV-exposed from age 6 weeks to 2 years is expressed as (1) percentage mortality, (2) risk ratio compared to the current strategy, (3) excess deaths per year relative to the current strategy, and (4) excess annual deaths per 100,000 compared to the current strategy. The number of infants who are HIV-exposed in each country was calculated based on the number of live births and proportion of mothers living with HIV [19].

Data Sources and Parameters

We included parameters to reflect child HIV status based on UNAIDS perinatal and postnatal transmission rates. The probability of an HIV test yielding a positive result was based on age-specific transmission rates, obtained from country-specific UNAIDS estimates from the most recent year with available data for all countries, including six-week transmission rates (MOZ 6%, ZWE 5%, CIV 4%, and UGA 3%) [2]. For postnatal transmission, we calculated the cumulative probability of acquiring HIV by age 9 months (MOZ 3.4%, ZWE 1.7%, CIV 1.7%, UGA 1.3%), and by the end of breastfeeding (MOZ 4.1%, ZWE 2.0%, CIV 2.1%, UGA 1.6%), based on derived weekly transmission rates from country-specific final vertical transmission rates and breastfeeding duration, making the assumption that postnatal transmission rates were consistent over time [16].

EID rates at 6 weeks were derived from country-specific UNAIDS estimates (MOZ 82.9%, ZWE 75.9%, UGA 66.2%, CIV 60.8%) [16]. Since data on subsequent testing are not available, we assumed that 80% of children undergoing EID would have a 9-month test, and 50% would have an EoB test, as these children would likely be engaged in the test-to-treatment cascade. For children not undergoing EID at 6 weeks, we assumed the probability of subsequent testing was much lower (10% for 9-month test, 30% for EoB), as these children were likely less engaged with services. We derived the proportion of children starting ART after a positive HIV test result based on point-of-care and standard-of-care testing coverage and corresponding ART uptake from a recent meta-analysis [17].

235 Scenarios

To estimate mortality, we considered several scenarios: (1) children with HIV diagnosed by EID, (2) children with HIV not yet diagnosed (due to missed 6-week, 9-month and/or EoB tests) or with postnatal acquisition after an earlier negative test, and (3) children who are HIV-exposed and uninfected.

In the first scenario, children with known positive HIV status after EID started cotrimoxazole, and 77% received ART based on a recent meta-analysis [17]. We applied a 43% mortality reduction following cotrimoxazole initiation based on results of the CHAP trial [7], and a 76% mortality reduction following ART initiation based on the CHER trial, to underlying mortality estimates [3,18].

In the second scenario, children had undiagnosed HIV and did not therefore receive ART. We based the survival probability on a pooled analysis of natural history studies conducted prior to the availability of ART [3], and applied a 43% mortality reduction due to cotrimoxazole alone. With the same rationale as in the first scenario, for 77% of children diagnosed with HIV (by 9 month or EoB testing), we applied mortality reduction of 76% from ART and 43% from cotrimoxazole.

In the third scenario, we derived mortality estimates for children who are HEU from an individual pooled analysis [15], and applied no mortality reduction due to cotrimoxazole, based on trial data [8,9].

Sensitivity Analyses

To explore uncertainties in the model assumptions, we conducted sensitivity analyses by adjusting estimates of cotrimoxazole uptake, mortality reduction from cotrimoxazole, vertical transmission rates (perinatal and postnatal), and EID testing rates. For cotrimoxazole, we considered the effect of lower uptake (40%, 60% and 80% of HIV-exposed children starting cotrimoxazole at age 6 weeks) compared to 100% uptake in the base model. For mortality effects of cotrimoxazole, we altered the base case assumption of 43% mortality reduction, derived from the CHAP trial, which compared cotrimoxazole and placebo among hospitalised children with HIV in Zambia. Since CHAP included very few infants, meaning mortality reductions are uncertain in children <12 months old, we used conservative estimates of 15%, 20%, 25%, 30%, 35%, 40% mortality reduction from cotrimoxazole to test a range of assumptions. To consider future progress in the prevention of MTCT, we reduced

perinatal MTCT in 1% decrements to 0% and, separately, reduced postnatal MTCT rates in 0.5% decrements to 0%. Finally, we increased EID coverage in 10% increments, from current country rates up to 100%, to estimate the mortality benefits of cotrimoxazole with improved testing coverage over time. In a final sensitivity analysis, we combined the variables above to create a conservative estimate of effects, assuming low levels of cotrimoxazole uptake (40%), low ascribed mortality reduction from cotrimoxazole (15%), low perinatal (1%) and postnatal (1%) vertical transmission, and optimal EID coverage (100%).

Data access and ethics

The model was constructed in Microsoft Excel, is freely available at https://osf.io/8kjgp/ and can be adapted for other settings. No ethical approval was sought for this modelling study.

Results

Modelling the current WHO strategy, predicted mortality was 5.58% for Zimbabwe, 5.59% for Côte d'Ivoire, 5.78% for Mozambique and 5.39% for Uganda. Limiting cotrimoxazole exposure from 6 weeks to 3 months of age, resulted in higher predicted mortality in each setting compared to the current strategy: Zimbabwe (increase in predicted mortality from 5.58% to 5.83%, risk ratio (RR) 1.04, predicted excess mortality rate 246 deaths per 100 000 infants HIV-exposed, or 334 excess annual deaths), Côte d'Ivoire (from 5.59% to 5.90%, RR 1.05, 304 deaths per 100 000, 118 excess deaths), Mozambique (from 5.78% to 6.11%, RR 1.06, 328 deaths per 100 000, 928 excess deaths), and Uganda (from 5.39% to 5.60%, RR 1.04, 209 deaths per 100 000, 466 excess deaths); Table 1 and Fig 2. Similar effects were observed for six-, nine- and twelve-month strategies: in each case, predicted infant mortality increased compared to the current policy, with the number of excess deaths lower with longer durations of cotrimoxazole prophylaxis (Table 1, Fig 2).

A programmatic strategy of no routine prophylaxis, and instead initiating cotrimoxazole only once HIV is diagnosed, led to the greatest increase in predicted mortality across settings: Zimbabwe (increase in predicted mortality from 5.58% to 5.84%, RR 1.05, predicted excess mortality rate 260 deaths per 100 000 infants HIV-exposed, 352 excess annual deaths), Côte d'Ivoire (from 5.59% to 5.91%, RR 1.06, 322 deaths per 100 000, or 125 excess deaths), Mozambique (from 5.78% to 6.12%, RR 1.06, 339 deaths per 100 000, or 961 excess deaths), and Uganda (from 5.39% to 5.61%, RR 1.04, 221 deaths per 100 000, 491 excess deaths); Table 1.

Sensitivity Analyses

Sensitivity analyses for Mozambique are shown in Fig 3. Reducing cotrimoxazole uptake to 40%, predicted excess mortality was lower overall, but the fewest predicted deaths still occurred under the current strategy of universal cotrimoxazole provision. Lowering the efficacy of cotrimoxazole in 5% intervals, to as little as 15% predicted mortality reduction (compared to 43% in the CHAP trial), the current strategy continued to have the lowest number of predicted deaths. When EID coverage was increased to 100%, the current strategy still had the lowest predicted mortality, compared to alternative approaches of shorter durations of cotrimoxazole, although predicted excess mortality reduced overall. To explore the effect of reaching and exceeding MTCT elimination targets, we reduced rates for both perinatal and postnatal vertical transmission to zero. Finally, a combined conservative estimate of low cotrimoxazole coverage (40%) and efficacy (15%), low vertical transmission (2%) and high EID (100%), designed to model a plausible future scenario in each country, showed the current strategy still led to fewer predicted deaths, though effects were attenuated.

Predicted mortality effects remained consistent across countries in all our sensitivity analyses. Mozambique has the highest vertical transmission rate of the four countries (13.5%), and high EID coverage (82.9%). If uptake was as low as 40% in Mozambique, starting cotrimoxazole only after a positive HIV test is estimated to result in 369 excess annual deaths compared to the current strategy (Fig 3). Figures for sensitivity analysis in Cote d'Ivoire (Fig S3.4), Zimbabwe (Fig S3.2), and Uganda (Fig S3.7) are available in the Supplement. Uganda has the lowest vertical transmission rate (5.9%) and EID coverage of 66.2%. Further reducing perinatal and postnatal MTCT without changing EID is estimated to result in 311 and 251 excess annual deaths, respectively, if a strategy of starting cotrimoxazole only after a positive HIV test was deployed. Cote d'Ivoire has the lowest EID coverage of the four countries (60.8%) and vertical transmission of 7.8%. In the most optimistic consideration, if EID coverage was increased to 100%, 3-month provision of cotrimoxazole is predicted to result in 51 excess annual deaths, in part due to continued vertical transmission through breastfeeding. In Zimbabwe, where the vertical transmission rate (8.7%) is similar to the regional estimate for Eastern and Southern Africa, a conservative ascribed mortality reduction to cotrimoxazole of 15% would still result in 352 excess annual deaths when cotrimoxazole is only started after a positive HIV test result.

Discussion

Our study suggests that changing the current cotrimoxazole policy for children born to mothers with HIV is predicted to result in more deaths across the four modelled high-burden settings representing different epidemic contexts. The highest increase in mortality is predicted to occur with no routine cotrimoxazole provision (ranging from predicted excess mortality rate of 221 per 100 000 for Uganda to 339 per 100 000 for Mozambique). These predicted effects persisted, but were attenuated, when modelling lower cotrimoxazole uptake, smaller mortality benefits from prophylaxis, higher EID coverage, and lower perinatal and postnatal vertical transmission. These effects are driven entirely by the benefits of cotrimoxazole for infants who acquire HIV. Even as the epidemic context matures and most infants now remain HIV-free, many countries still have slow progress towards elimination targets. This study demonstrates the important 'safety net' that cotrimoxazole may provide for children who are missed by the test-to-treat cascade in these settings.

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

338

339

340

341

342

343

344

345

346

347

348

Recent studies have questioned the ongoing value of cotrimoxazole in settings where most children born to women with HIV now remain HIV-free [8-10]. Our study shows that across these four modelled settings, predicted mortality would increase by limiting provision of cotrimoxazole. When comparing modelled strategies, the highest predicted mortality occurred under an alternative strategy of providing no universal prophylaxis, and instead starting cotrimoxazole only after a positive infant HIV test result. This is driven by high predicted mortality among infants with HIV who are not picked up by testing, and therefore not started on ART or cotrimoxazole [6,7]. Predicted mortality increased to different degrees when cotrimoxazole was given universally but for a shorter duration than currently. This is due to inadequate EID coverage, vertical transmission through breastfeeding after an initial negative test, and shortening cotrimoxazole duration during a period when disease progression among children with HIV remains rapid [3]. While the benefits of retaining the current strategy persisted even with suboptimal cotrimoxazole coverage, reflecting the reality in many settings, there were fewer benefits with low coverage, emphasising the continued effort needed to retain infants in care [20]. When comparing countries, Mozambique had the highest predicted excess mortality and greatest number of excess annual deaths under alternative cotrimoxazole strategies. This likely reflects high perinatal and postnatal transmission in Mozambique compared to the other modelled countries. Conversely, Uganda has the lowest MTCT rates, having made significant progress towards the elimination of paediatric HIV, and lowest predicted increase in mortality with alternative cotrimoxazole strategies. Mozambique has the highest EID testing rate but also had the greatest estimated increase in predicted mortality in our models [16]. Taken together, this suggests that while increased testing coverage is advantageous, continued focus should be placed on interventions to reduce vertical transmission. Where vertical transmission does occur, timely testing and initiation of antiretroviral treatment remains a

cornerstone of care. Countries with ongoing high rates of transmission would be most affected by any change in cotrimoxazole strategy.

There are several strengths and limitations to the analysis. Our model was developed with up-todate, publicly available epidemiological estimates. These were supplemented by data extracted from the highest available levels of evidence. The model incorporates multiple aspects of transmission, testing and treatment uptake and mortality, and has been developed in an accessible format which can be adapted to other settings. Assumptions in the model were interrogated in sensitivity analyses. Although our effects of cotrimoxazole were derived from the CHAP trial – which enrolled children after infancy in the pre-ART era – fewer predicted deaths occurred under the current strategy even when the estimated mortality reduction from cotrimoxazole was as low as 15%. There are limited randomised controlled trial data for cotrimoxazole among breastfed infants with HIV, but it is unlikely that mortality benefits are substantially lower than in the original CHAP trial, given the more rapid disease progression at this age, lack of prognostic markers, and higher risk of Pneumocystis jirovecii pneumonia. Our sensitivity analysis shows that, even if this assumption is untrue and the benefits are much lower, the current policy leads to fewer predicted deaths than a revised policy of shorter (or no) prophylaxis. There are also limitations to this analysis. There are several parameters for which data were not available (e.g., the probability of having a 9-month test if early infant diagnosis has been missed). We assumed equal uptake of cotrimoxazole regardless of final child HIV status, but it is likely that children most likely to acquire HIV are the least engaged in care and are therefore less likely to receive cotrimoxazole. Countries achieving 95-95-95 testing and treatment targets and Path to Elimination of MTCT goals were not modelled and may no longer require routine cotrimoxazole given that few infants acquire HIV and those who do are most likely to be missed by testing [21].

We only modelled mortality increases following reductions in cotrimoxazole provision, given the known benefits of cotrimoxazole for children with HIV; however, our goal was to quantify the magnitude of mortality increase for each strategy across epidemic contexts to provide policymakers with population estimates when considering guideline revisions. We recognise, however, that our model did not incorporate the potential risks of cotrimoxazole, such as antimicrobial resistance, as mortality effects are difficult to quantify given limited quality data from sub-Saharan Africa [22]. There is evidence that cotrimoxazole use in infants who are HEU leads to antimicrobial resistance, including one small study showing cross-class resistance to amoxicillin, but no evidence of major microbiome dysbiosis from available data [23]. Although there are estimates of deaths attributable to resistance for specific antibiotics in several global regions [24], it is difficult to model what

proportion of these deaths would be averted in each of our scenarios, particularly as it remains unclear whether cotrimoxazole resistance is reversible to a clinically relevant level with decline in use [25]. Estimates of pathogen-specific deaths attributable to AMR from cotrimoxazole in sub-Saharan Africa in the post-neonatal period range from 0.0 (0.0-0.1) per 100 000 for *Proteus spp.* to 15.07 (2.3-31.8) per 100 000 for *Streptococcus pneumoniae*, but even collectively these estimates are much lower than the excess deaths modelled in our programmatic scenarios from restricted cotrimoxazole use. Responsive country-level surveillance is required to evaluate local resistance data in the context of evolving HIV epidemics. Lastly, this study did not consider the economic implications of the proposed strategies. Future research should investigate the potential cost savings and the financial impacts of implementing each strategy on national budgets [26].

418 419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

408

409

410

411

412

413

414

415

416

417

Countries need to continue to strengthen the test-to-treat cascade, to ensure timely testing and ART initiation, in order to reduce morbidity and mortality among infants who are HIV-exposed. However, our models show that cotrimoxazole still remains an important part of the package of care. Decisions around appropriate provision of cotrimoxazole to infants who are HIV-exposed require a pragmatic, public health approach with difficult decisions that weigh risks and benefits that differ across settings. Results from this model may be considered as part of the breadth of evidence which help inform policymaker decisions. Though there has been progress in prevention of paediatric HIV, the 'last mile' to elimination is particularly challenging. Furthermore, in many high-burden settings, testing coverage is not universal, making it difficult to reliably distinguish infants who are HIVinfected or HEU. Individualised algorithms dependent on testing contingencies may be unrealistic given resource and service limitations at most low-level health facilities. The current programmatic cotrimoxazole strategy provides important benefits for the small number of high-risk infants who still acquire HIV through vertical transmission and are missed due to gaps in the test-to-treat cascade. As demonstrated in the sensitivity analysis for each strategy, lower vertical transmission rates and improved testing and treatment uptake attenuate the predicted increase in mortality. This demonstrates the importance of considering how vertical transmission should inform cotrimoxazole policy: in the context of high ongoing transmission, the current universal cotrimoxazole prophylaxis approach is predicted to lead to substantially fewer deaths than alternative strategies, while settings with low transmission rates may derive less benefit from universal cotrimoxazole prophylaxis. Therefore, hybrid cotrimoxazole policies may be a consideration noting we did not model countries achieving HIV elimination targets or with strong test-to-treat cascades. Further research is required to better understand cotrimoxazole coverage for children who are HIV-exposed; to determine the proportion who are subsequently found to be living with HIV; to better understand community values and preferences; and to identify barriers to engagement with the test-to-treat cascade.

Finally, cost-effectiveness analysis informed by national programme cost data is required to better understand the most optimal health investment and cost per death averted and economic impact of each strategy.

In conclusion, despite impressive progress in prevention of vertical HIV transmission, elimination is not yet in sight in most high-burden settings. Priorities include maintaining optimal care and ART for mothers; providing postnatal HIV prophylaxis for infants; and ensuring timely testing and linkage to care. However, cotrimoxazole continues to provide a vital safety net for infants who acquire HIV but are not tested or started on ART. Our data suggest that changing the current strategy of universal cotrimoxazole provision for all infants who are HIV-exposed would increase predicted mortality to varying degrees across the four modelled countries, depending on vertical transmission rates and test-to-treatment cascade coverage. Policymakers need to balance the possible negative effects of cotrimoxazole with potential excess deaths resulting from changes in programmatic use depending on their specific context.

Acknowledgements

This work was originally presented at the International Workshop on HIV Pediatrics 2021.

References

- 471 1. Joint United Nations Programme on HIV/AIDS. UNAIDS data 2022. Geneva: UNAIDS, 2022.
- 472 2. Joint United Nations Programme on HIV/AIDS. Start Free, Stay Free, AIDS Free Final report on 473 2020 targets. 2021.
- 474 3. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of
- infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet.
- 476 2004;364(9441):1236-43. doi: 10.1016/S0140-6736(04)17140-7. PubMed PMID: 15464184.
- 477 4. World Health Organization. Guidelines on post-exposure prophylaxis for HIV and the use of
- 478 co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children:
- 479 recommendations for a public health approach: December 2014 supplement to the 2013
- 480 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.
- 481 World Health Organization; 2014.
- 482 5. Church JA, Fitzgerald F, Walker AS, Gibb DM, Prendergast AJ. The expanding role of co-
- trimoxazole in developing countries. Lancet Infect Dis. 2015;15(3):327-39. Epub 20150121. doi:
- 484 10.1016/S1473-3099(14)71011-4. PubMed PMID: 25618179.
- 485 6. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo
- 486 K, et al. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J
- 487 Med. 2014;370(1):41-53. doi: 10.1056/NEJMoa1214901. PubMed PMID: 24382064; PubMed Central
- 488 PMCID: PMCPMC4264559.
- 489 7. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as
- 490 prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind
- 491 randomised placebo-controlled trial. Lancet. 2004;364(9448):1865-71. doi: 10.1016/S0140-
- 492 6736(04)17442-4. PubMed PMID: 15555666.
- 493 8. Daniels B, Coutsoudis A, Moodley-Govender E, Mulol H, Spooner E, Kiepiela P, et al. Effect of
- 494 co-trimoxazole prophylaxis on morbidity and mortality of HIV-exposed, HIV-uninfected infants in
- 495 South Africa: a randomised controlled, non-inferiority trial. Lancet Glob Health. 2019;7(12):e1717-
- 496 e27. doi: 10.1016/S2214-109X(19)30422-X. PubMed PMID: 31708152.
- 497 9. Lockman S, Hughes M, Powis K, Ajibola G, Bennett K, Moyo S, et al. Effect of co-trimoxazole
- on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind,
- randomised, placebo-controlled trial. Lancet Glob Health. 2017;5(5):e491-e500. doi: 10.1016/S2214-
- 500 109X(17)30143-2. PubMed PMID: 28395844; PubMed Central PMCID: PMCPMC5502726.
- 501 10. Daniels B, Kuhn L, Spooner E, Mulol H, Goga A, Feucht U, et al. Cotrimoxazole guidelines for
- infants who are HIV-exposed but uninfected: a call for a public health and ethics approach to the
- 503 evidence. Lancet Glob Health. 2022;10(8):e1198-e203.
- Teasdale CA, Zimba R, Abrams EJ, Sachathep K, Ndagije F, Nuwagaba-Biribonwoha H, et al.
- 505 Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho,
- Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the
- 507 cross-sectional Population-based HIV Impact Assessment surveys. Lancet HIV. 2022;9(2):e91-e101.
- 508 doi: 10.1016/S2352-3018(21)00291-5. PubMed PMID: 35120641.
- 509 12. Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-
- 1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more
- 511 cost-effective interventions. BMC Med. 2011;9:59. Epub 20110520. doi: 10.1186/1741-7015-9-59.
- PubMed PMID: 21599888; PubMed Central PMCID: PMCPMC3129310.
- 513 13. Chatterjee A, Tripathi S, Gass R, Hamunime N, Panha S, Kiyaga C, et al. Implementing services
- for Early Infant Diagnosis (EID) of HIV: a comparative descriptive analysis of national programs in four
- 515 countries. BMC Public Health. 2011;11:553. Epub 20110713. doi: 10.1186/1471-2458-11-553.
- PubMed PMID: 21749730; PubMed Central PMCID: PMCPMC3161890.
- 517 14. Wedderburn CJ, Evans C, Slogrove AL, Rehman AM, Gibb DM, Prendergast AJ, et al. Co-
- 518 trimoxazole prophylaxis for children who are HIV-exposed and uninfected: a systematic review. J Int
- 519 AIDS Soc. 2023;26(6):e26079. doi: 10.1002/jia2.26079. PubMed PMID: 37292018; PubMed Central
- 520 PMCID: PMCPMC10251133.

- 521 15. Arikawa S, Rollins N, Jourdain G, Humphrey J, Kourtis AP, Hoffman I, et al. Contribution of
- 522 Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human
- 523 Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and
- 524 Asian Studies. Clin Infect Dis. 2018;66(11):1668-77. doi: 10.1093/cid/cix1102. PubMed PMID:
- 525 29272387; PubMed Central PMCID: PMCPMC5961296.
- 526 16. Joint United Nations Programme on HIV/AIDS. UNAIDS data 2021. Geneva: UNAIDS, 2021.
- 527 17. Luo R, Fong Y, Boeras D, Jani I, Vojnov L. The clinical effect of point-of-care HIV diagnosis in
- infants: a systematic review and meta-analysis. Lancet. 2022;400(10356):887-95. doi:
- 529 10.1016/S0140-6736(22)01492-1. PubMed PMID: 36116479.
- 530 18. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral
- therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233-44. doi:
- 532 10.1056/NEJMoa0800971. PubMed PMID: 19020325; PubMed Central PMCID: PMCPMC2950021.
- 533 19. World Bank. World development indicators 2022. https://data.worldbank.org/: The World
- 534 Bank; 2022. Accessed 2022 Dec 2.
- 535 20. Mofenson LM, Cohn J, Sacks E. Challenges in the early infant HIV diagnosis and treatment
- cascade. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2020;84:S1-S4.
- 537 21. Frescura L, Godfrey-Faussett P, Feizzadeh AA, El-Sadr W, Syarif O, Ghys PD, et al. Achieving
- the 95 95 95 targets for all: A pathway to ending AIDS. PLoS One. 2022;17(8):e0272405. Epub
- 20220804. doi: 10.1371/journal.pone.0272405. PubMed PMID: 35925943; PubMed Central PMCID:
- 540 PMCPMC9352102.
- 541 22. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, Gonzalez IJ, et al.
- Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17(1):616. Epub
- 20170911. doi: 10.1186/s12879-017-2713-1. PubMed PMID: 28893183; PubMed Central PMCID:
- 544 PMCPMC5594539.

- 545 23. Powis KM, Souda S, Lockman S, Ajibola G, Bennett K, Leidner J, et al. Cotrimoxazole
- prophylaxis was associated with enteric commensal bacterial resistance among HIV-exposed infants
- in a randomized controlled trial, Botswana. J Int AIDS Soc. 2017;20(3). doi: 10.1002/jia2.25021.
- PubMed PMID: 29119726; PubMed Central PMCID: PMCPMC5810322.
- 549 24. Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a
- 550 systematic analysis. Lancet. 2022;399(10325):629-55. Epub 20220119. doi: 10.1016/S0140-
- 551 6736(21)02724-0. PubMed PMID: 35065702; PubMed Central PMCID: PMCPMC8841637.
- 552 25. Pouwels KB, Batra R, Patel A, Edgeworth JD, Robotham JV, Smieszek T. Will co-trimoxazole
- resistance rates ever go down? Resistance rates remain high despite decades of reduced co-
- trimoxazole consumption. J Glob Antimicrob Resist. 2017;11:71-4. Epub 20170731. doi:
- 555 10.1016/j.jgar.2017.07.013. PubMed PMID: 28774863.
- 556 26. Ryan M, Griffin S, Chitah B, Walker AS, Mulenga V, Kalolo D, et al. The cost-effectiveness of
- cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS. 2008;22(6):749-57. doi:
- 558 10.1097/QAD.0b013e3282f43519. PubMed PMID: 18356605.

Tables and Figures

Table 1 Comparison of predicted mortality, between ages 6 weeks to 2 years, with different programmatic cotrimoxazole strategies for children born to mothers with HIV. For the current WHO strategy (base case) of providing cotrimoxazole (CTX) to all HIV-exposed children, mortality rate is expressed in percent (%). Alternative strategies explored were (1) initiating cotrimoxazole at 6 weeks and stopping at 12 months, (2) initiating cotrimoxazole at 6 weeks and stopping at 9 months, (3) initiating cotrimoxazole at 6 weeks and stopping at 3 months, and (5) initiating cotrimoxazole prophylaxis only once a positive HIV test result is confirmed. Mortality for alternative strategies are reported in comparison to the base case (current strategy): risk ratio, excess mortality rate per 100 000 HIV-exposed infants, and excess annual deaths. CTX = cotrimoxazole.

Fig 1 Schematic illustration of model structure (scenarios and strategies). Panel A (Scenarios):

Scenarios considered were (1) children with HIV (diagnosed), (2) children with HIV (undiagnosed), or (3) HEU. Superscripts denote applied mortality estimates: (a) age-specific baseline mortality estimates for infants with HIV and no ART, based on Newell et al. [3]. (b) age-specific baseline mortality estimates for HIV-exposed uninfected infants based on Arikawa et al. [15], (c) 77% uptake of ART following positive HIV test based on Luo et al. [17], (d) 76% mortality reduction from ART based on CHER [18], (e) 43% mortality reduction from CTX in a child with HIV based on CHAP [7], (f) 0% mortality reduction from CTX in an HIV-exposed uninfected child based on Botswana and South Africa trials [8, 9]. Panel B (Strategies): Illustration of considered programmatic strategies. Pink represents period of programmatic CTX provision. Blue represents period of risk of HIV transmission due to breastfeeding (18 months). Strategies illustrated are (1) current WHO strategy (2) initiating CTX at 6 weeks and stopping at 12 months, (3) initiating CTX at 6 weeks and stopping at 9 months, (4) initiating CTX at 6 weeks and stopping at 3 months, and (6) initiating CTX prophylaxis only once a positive HIV test result is confirmed and the child is started on ART. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis at 6 weeks, 9mo = 9-month HIV test, EoB = end of breastfeeding.

Fig 2 Excess deaths per year by country under alternative cotrimoxazole strategies. Columns represent additional deaths from each alternate strategy in comparison to the current WHO programmatic strategy of providing cotrimoxazole to all HIV-exposed infants. 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

Fig 3 Sensitivity Analysis (Mozambique) - Conservative Scenarios. Sensitivity analysis exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) compared to the current WHO strategy for Mozambique: (1) Cotrimoxazole uptake at 40% rather than 100% assumed in the base model, (2) Mortality reduction from cotrimoxazole while on antiretroviral therapy decreased from 43% to 15% (3) Mortality reduction from cotrimoxazole while not on antiretroviral therapy decreased from 43% to 15% (4) EID coverage increased to 100% rather than 82.9% EID coverage for Mozambique, (5) Perinatal MTCT reduced from to 6% to 1%, (6) Postnatal MTCT decreased from 7.5% to 6.5%. (7) Conservative estimate concurrently combining sensitivity scenarios 1-6. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. Supplement Table S1: Model assumptions and data sources. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis at 6 weeks, ZIM = Zimbabwe, CIV = Cote d'Ivoire, MOZ = Mozambique, UGA = Uganda. *The authorship brings multidisciplinary expertise in paediatric HIV (AJP, CE, DMG, CW, MP), epidemiology (MS, DMG), clinical trials (DMG, AJP, MP, MS) and policy (SM, MP). Fig S2.1 Predicted mortality percentage per year by country under alternative cotrimoxazole strategies. Columns represent additional deaths from each alternate strategy in comparison to the current WHO programmatic strategy of providing cotrimoxazole to all HIV-exposed infants. 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. Fig S2.2 Predicted excess mortality rate (per 100 000) per year by country under alternative cotrimoxazole strategies. Columns represent additional deaths from each alternate strategy in comparison to the current WHO programmatic strategy of providing cotrimoxazole to all HIVexposed infants. 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. Fig S2.3 Predicted risk ratio per year by country under alternative cotrimoxazole strategies. Columns represent additional deaths from each alternate strategy in comparison to the current WHO programmatic strategy of providing cotrimoxazole to all HIV-exposed infants. 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. Fig S3.1 Sensitivity Analysis for Zimbabwe (Risk Ratios). Sensitivity analysis, for Zimbabwe, exploring

the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) compared to the

current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611612

613

614

615

616

617

618

619

620

621

622

623

624

625

626627

628

630 at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 631 3m = 3 months. 632 633 Fig S3.2 Sensitivity Analysis for Zimbabwe (Excess Deaths). Sensitivity analysis, for Zimbabwe, 634 exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) 635 compared to the current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = 636 early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 637 months, 6m = 6 months, 3m = 3 months. 638 639 Fig S3.3 Sensitivity Analysis for Cote d'Ivoire (Risk Ratios). Sensitivity analysis, for Cote d'Ivoire, 640 exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) 641 compared to the current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = 642 early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 643 months, 6m = 6 months, 3m = 3 months. 644 645 Fig S3.4 Sensitivity Analysis for Cote d'Ivoire (Excess Deaths). Sensitivity analysis, for Cote d'Ivoire, 646 exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) 647 compared to the current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = 648 early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 649 months, 6m = 6 months, 3m = 3 months. 650 651 Fig S3.5 Sensitivity Analysis for Mozambique (Risk Ratios). Sensitivity analysis, for Mozambique, 652 exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) 653 compared to the current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = 654 early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 655 months, 6m = 6 months, 3m = 3 months. 656 657 Fig S3.6 Sensitivity Analysis for Uganda (Risk Ratios). Sensitivity analysis, for Uganda, exploring the 658 effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) compared to the 659 current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis 660 at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 661 3m = 3 months. 662 Fig S3.7 Sensitivity Analysis for Uganda (Excess Deaths). Sensitivity analysis, for Uganda, exploring 663

the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) compared to the

665 current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis 666 at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 667 3m = 3 months. 668 669 Fig S4.1 Sensitivity Variable - Cotrimoxazole Uptake, Zimbabwe. Risk ratio of mortality for varying 670 risk reduction from cotrimoxazole uptake for Zimbabwe, (Risk Ratio). CTX = cotrimoxazole, 12m = 12 671 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 672 673 Fig S4.2 Sensitivity Variable – Risk Reduction from CTX, Zimbabwe. Risk ratio of mortality for varying 674 risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for Zimbabwe, 675 (Risk Ratio). Risk reduction from 15%-43%. CTX = cotrimoxazole, ART = antiretroviral therapy, 12m = 676 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 677 678 Fig S4.3 Sensitivity Variable – Risk Reduction from CTX, Zimbabwe. Risk ratio of mortality for varying 679 risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for Zimbabwe, 680 (Risk Ratio). Risk Reduction from 25%-60%. CTX = cotrimoxazole, ART = antiretroviral therapy, 12m = 681 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 682 683 Fig S4.4 Sensitivity Variable – EID Testing, Zimbabwe. Risk ratio of mortality for varying probability 684 of HIV-exposed infants undergoing Early Infant Diagnosis (EID) for Zimbabwe, (Risk Ratio). EID = early 685 infant diagnosis at 6 weeks, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 686 687 Fig S4.5 Sensitivity Variable – Perinatal MTCT, Zimbabwe. Risk ratio of mortality for varying 688 probability of perinatal mother-to-child transmission (MTCT) for Zimbabwe, (Risk Ratio). MTCT = 689 mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 690 691 Fig S4.6 Sensitivity Variable – Postnatal MTCT, Zimbabwe. Risk ratio of mortality for varying 692 probability of post-natal mother-to-child transmission (MTCT) for Zimbabwe, (Risk Ratio). MTCT = 693 mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 694 695 Fig S4.7 Sensitivity Variable - Cotrimoxazole Uptake, Cote d'Ivoire. Risk ratio of mortality for varying 696 risk reduction from cotrimoxazole uptake for Cote d'Ivoire, (Risk Ratio). CTX = cotrimoxazole, 12m = 697 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

699 Fig S4.8 Sensitivity Variable – Risk Reduction from CTX, Cote d'Ivoire. Risk ratio of mortality for 700 varying risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for 701 Cote d'Ivoire, (Risk Ratio). Risk reduction from 15%-43%. CTX = cotrimoxazole, ART = antiretroviral 702 therapy, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 703 704 Fig S4.9 Sensitivity Variable – Risk Reduction from CTX, Cote d'Ivoire. Risk ratio of mortality for 705 varying risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for 706 Cote d'Ivoire, (Risk Ratio). Risk reduction from 15%-60%. CTX = cotrimoxazole, ART = antiretroviral 707 therapy, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 708 709 Fig S4.10 Sensitivity Variable – EID Testing, Cote d'Ivoire. Risk ratio of mortality for varying 710 probability of HIV-exposed infants undergoing Early Infant Diagnosis (EID) for Cote d'Ivoire, (Risk 711 Ratio). EID = early infant diagnosis at 6 weeks, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m 712 = 3 months. 713 714 Fig S4.11 Sensitivity Variable - Perinatal MTCT, Cote d'Ivoire. Risk ratio of mortality for varying 715 probability of perinatal mother-to-child transmission (MTCT) for Cote d'Ivoire, (Risk Ratio). MTCT = 716 mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 717 718 Fig S4.12 Sensitivity Variable – Postnatal MTCT, Cote d'Ivoire. Risk ratio of mortality for varying 719 probability of post-natal mother-to-child transmission (MTCT) for Cote d'Ivoire, (Risk Ratio). MTCT = 720 mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 721 722 Fig S4.13 Sensitivity Variable - Cotrimoxazole Uptake, Mozambique. Risk ratio of mortality for 723 varying risk reduction from cotrimoxazole uptake for Mozambique, (Risk Ratio). CTX = cotrimoxazole, 724 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 725 726 Fig S4.14 Sensitivity Variable – Risk Reduction from CTX, Mozambique. Risk ratio of mortality for 727 varying risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for 728 Mozambique, (Risk Ratio). Risk reduction from 15%-43%. CTX = cotrimoxazole, ART = antiretroviral 729 therapy, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 730 731 Fig S4.15 Sensitivity Variable – Risk Reduction from CTX, Mozambique. Risk ratio of mortality for 732 varying risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for

733 Mozambique, (Risk Ratio). Risk reduction from 15%-60%. CTX = cotrimoxazole, ART = antiretroviral 734 therapy, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 735 736 Fig S4.16 Sensitivity Variable - EID Testing, Mozambique. Risk ratio of mortality for varying probability of HIV-exposed infants undergoing Early Infant Diagnosis (EID) for Mozambique, (Risk 737 738 Ratio). EID = early infant diagnosis at 6 weeks, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m 739 = 3 months. 740 741 Fig S4.17 Sensitivity Variable – Perinatal MTCT, Mozambique. Risk ratio of mortality for varying 742 probability of perinatal mother-to-child transmission (MTCT) for Mozambique, (Risk Ratio). MTCT = 743 mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 744 745 Fig S4.18 Sensitivity Variable – Postnatal MTCT, Mozambique. Risk ratio of mortality for varying 746 probability of post-natal mother-to-child transmission (MTCT) for Mozambique, (Risk Ratio). MTCT = 747 mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 748 749 Fig S4.19 Sensitivity Variable - Cotrimoxazole Uptake, Uganda. Risk ratio of mortality for varying risk 750 reduction from cotrimoxazole uptake for Uganda, (Risk Ratio). CTX = cotrimoxazole, 12m = 12 751 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 752 753 Fig S4.20 Sensitivity Variable – Risk Reduction from CTX, Uganda. Risk ratio of mortality for varying 754 risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for Uganda, 755 (Risk Ratio). Risk reduction from 15%-43%. CTX = cotrimoxazole, ART = antiretroviral therapy, 12m = 756 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 757 758 Fig S4.21 Sensitivity Variable – Risk Reduction from CTX, Uganda. Risk ratio of mortality for varying 759 risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for Uganda, 760 (Risk Ratio). Risk reduction from 15%-60%. CTX = cotrimoxazole, ART = antiretroviral therapy, 12m = 761 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 762 763 Fig S4.22 Sensitivity Variable - EID Testing, Uganda. Risk ratio of mortality for varying probability of 764 HIV-exposed infants undergoing Early Infant Diagnosis (EID) for Uganda, (Risk Ratio). EID = early 765 infant diagnosis at 6 weeks, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

Fig S4.23 Sensitivity Variable – Perinatal MTCT, Uganda. Risk ratio of mortality for varying probability of perinatal mother-to-child transmission (MTCT) for Uganda, (Risk Ratio). MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

Fig S4.24 Sensitivity Variable – Postnatal MTCT, Uganda. Risk ratio of mortality for varying probability of post-natal mother-to-child transmission (MTCT) for Uganda, (Risk Ratio). MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

		Programmatic Strategy					
		Current	Alternative				
			CTX from 6 weeks to 12 months	CTX from 6 weeks to 9 months	CTX from 6 weeks to 6 months	CTX from 6 weeks to 3 months	Start CTX only after positive HIV test result
Mozambique	Mortality (%) Risk Ratio Excess mortality rate (per 100000) Excess deaths per year	5.78 - -	5.91 1.02 131 371	5.95 1.03 174 492	6.07 1.05 295 835	6.11 1.06 328 928	6.12 1.06 339 961
Cote d'Ivoire	Mortality (%) Risk Ratio Excess mortality rate (per 100000) Excess deaths per year	5.59 - -	5.72 1.02 127 49	5.76 1.03 172 67	5.85 1.05 254 98	5.90 1.06 304 118	5.91 1.06 322 125
Zimbabwe	Mortality (%) Risk Ratio Excess mortality rate (per 100000) Excess deaths per year	5.58 - -	5.68 1.02 99 135	5.71 1.02 134 181	5.79 1.04 208 281	5.83 1.04 246 334	5.84 1.05 260 352
Uganda	Mortality (%) Risk Ratio Excess mortality rate (per 100000) Excess deaths per year	5.39 - - -	5.48 1.02 87 193	5.51 1.02 117 261	5.57 1.03 177 394	5.60 1.04 209 466	5.61 1.04 221 491

∄ Table 1




Fig1A




Fig1B




Fig2




Fig3